论文部分内容阅读
目的:评价β2-微球蛋白(B2M)作为预测人类免疫缺陷病毒(HIV)感染者病情进展及抗逆转录病毒治疗(HAART)效果评估标志物的价值。方法:3 145例标本分为4组,分别按试剂盒操作说明检测CD4+、CD8+细胞数、HIV病毒载量及B2M水平。结果:初次诊断HIV感染未接受HAART治疗组(Ⅰ组)与接受规则HAART治疗无症状组(Ⅱ组)B2M水平差异不显著(P>0.05);与对照组及接受不规则HAART治疗组(Ⅲ组)比较,差异显著(P<0.001)。3组间CD4+、CD8+计数、CD4+/CD8+比值、病毒载量差异显著(P<0.001);B2M水平与CD4+、CD8+计数、CD4+/CD8+比值呈负相关,与病毒载量呈正相关。结论:B2M是一个良好的预测HIV感染者病情进展及抗逆转录病毒治疗监测的标志物。
PURPOSE: To evaluate the value of β2-microglobulin (B2M) as a marker for predicting the progression of human immunodeficiency virus (HIV) infection and evaluating the effect of antiretroviral therapy (HAART). Methods: A total of 3 145 specimens were divided into 4 groups. The CD4 + and CD8 + cell count, HIV viral load and B2M level were detected by kit instructions. Results: There was no significant difference in the level of B2M between the first diagnosis of HIV infection in HAART group (group Ⅰ) and the treatment of asymptomatic HAART group (Ⅱ group) (P> 0.05). Compared with the control group and the irregular HAART group Group), the difference was significant (P <0.001). The levels of CD4 +, CD8 +, CD4 + / CD8 +, and viral load were significantly different among the three groups (P <0.001). The level of B2M was negatively correlated with the ratio of CD4 +, CD8 + and CD4 + / CD8 +. Conclusion: B2M is a good predictor of disease progression in HIV-infected individuals and an indicator of antiretroviral therapy monitoring.